1. Stats
  2. USPTO
  3. TC 1600
  4. Group 1640
  5. Art Unit 1646
  6. Examiner Reddig

Examiner Reddig Peter J

1646-REDDIG-PETER-J

Employment Information

Art Unit:1646 — Drug, bio-affecting and body treating compositions
Group:1640 — Immunology including antibodies, B&T lymphocytes, antigen presenting cells and Gram-positive/Negative Bacteria, Parasitic and Fungal Immunology
Classes: 424 — Drug, bio-affecting and body treating compositions
435 — Chemistry: molecular biology and microbiology
514 — Drug, bio-affecting and body treating compositions
530 — Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
600 — Surgery
506 — Combinatorial chemistry technology: method, library, apparatus
Phone:(571) 272-9031
Email:peter.reddig@uspto.gov
Location:VA 22314
Title:Pat Examnr Biomedical Engrg
Service:20 years
Grade:GS-14

Grant Rate and Difficulty Ranking

72
3-Year Grant rate: 60% over 366 cases
Difficulty: Harder
Difficulty Percentile: 72nd

With Examiner Reddig, you have a 60% chance of getting an issued patent by 3 years after the first office action. Examiner Reddig is a harder examiner and in the 72nd percentile across all examiners (with 100th percentile most difficult).

Grant Rate

Grant Rate Timeline

Below is the grant rate timeline for Examiner Reddig, where the timeline is relative to the date of the first office action. The three-year grant rate is the percentage of applications granted at three years after the first office action.

Comparison with Art Unit 1646

Examiner Reddig's grant rate is higher than that of Art Unit 1646 and lower than that of the USPTO.

Average Office Actions Per Grant
Examiner Reddig 2.0
Art Unit 1646 1.5

Interview Benefit

Grant Rate without Interview

Examiner Reddig has granted 180 of 303 cases without any applicant-requested interviews for a grant rate of 59%.

Grant Rate with Interview

Examiner Reddig has granted 40 of 63 cases with at least one applicant-requested interview for a grant rate of 63%.

Interview Benefit

With Examiner Reddig, conducting an interview increases your chance of getting a patent granted by 7%.

Recent Dispositions

Recent Dispositions

Number Title OA Rejections Status IFW
18666657 Composition Comprising Hdac Inhibitor And Immune Checkpoin Inhibitor And Methods For Using The Same Rejection information available with a Premium Stats subscription. See our pricing. Abandoned View
17918417 Treating Or Preventing Travelers Diarrhea Abandoned View
18953634 Methods And Compositions For Dosing Of Allogeneic Chimeric Antigen Receptor T Cells Patented View
16958614 Meditope-Enabled T Cells Patented View
17801458 Novel Methods For Creating Alpha-N-Methylated Polypeptides Abandoned View
18331859 Anti-Cd20 Antibody And Uses Thereof Patented View
17907648 Chimeric Antigen Receptors Targeting Cd33 Patented View
17953114 Anti-Muc16 Antibodies, Antibody-Drug Conjugates, And Bispecific Antigen-Binding Molecules That Bind Muc16 And Cd3, And Uses Thereof Patented View
16968547 Cyclin A1 Specific T Cell Receptors And Uses Thereof Patented View
17535898 Therapeutic And Diagnostic Methods For Cancer Abandoned View
17718513 Benzoquinone Derivatives For The Treatment Of Bladder Cancer Abandoned View
17469549 Pd-1 Polypeptide Variants Patented View
17292102 Methods And Compositions Relating To Anti-Chi3l1 Antibody Reagents For The Treatment Of Fibrosis Abandoned View
19276860 Compositions And Methods Related To Gprc5d Binding Agents And Variants Thereof Patented View
17609972 Ultraspecific Cell Targeting Using De Novo Designed Co-Localization Dependent Protein Switches Abandoned View
18374956 Engineered Immune Cells Targeting Bcma And Their Uses Thereof Patented View
17725240 Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating Cancer Patented View
16599988 Treatment Of Cancer Using Chimeric Antigen Receptor Abandoned View
17438051 Detection Means, Compositions And Methods For Modulating Synovial Sarcoma Cells Abandoned View
18331855 Anti-Cd20 Antibody And Uses Thereof Patented View
16950296 Anti-Cd79 Chimeric Antigen Receptors, Car-T Cells, And Uses Thereof Patented View
18331556 Improved Dual Specificity Polypeptide Molecule Abandoned View
18309303 Lag-3 Targeted Heterodimeric Fusion Proteins Containing Il-15/il-15ra Fc-Fusion Proteins And Lag-3 Antigen Binding Domains Patented View
17364270 Hybrid Immunoglobulin Containing Nonpeptidyl Linkage Patented View
17734512 Dna Vaccine Against Amyloid-Beta And Tau Abandoned View
18042763 Modified Cas9 System Having A Dominant Negative Effector On Non-Homologous End-Joining Fused Thereto And Its Use For Improved Gene Editing Patented View
17420739 Bispecific In Tandem Receptor Car And Method For Modulating The Tumoral Microenvironment Patented View
18409191 Immunocompetent Cell That Expresses A Cell Surface Molecule Specifically Recognizing Human Mesothelin, Il-7 And Ccl19 Abandoned View
17202173 Determinants Of Cancer Response To Immunotherapy By Pd-1 Blockade Patented View
17817308 Constructs Specifically Recognizing Glypican 3 And Uses Thereof Patented View
17630391 Method For Treatment Of Hepatic Cancer Using Reic/dkk-3 Gene In Combination With Anti-Tumor Agent Abandoned View
17586984 Antibodies Binding To Gprc5d Abandoned View
17290065 Methods For Treatment Using Chimeric Antigen Receptors Specific For B-Cell Maturation Antigen Patented View
17954070 Methods Of Conditioning Patients For T Cell Therapy Patented View
16633549 Collagen Encapsulation Of Insulin-Producing Cells Patented View
18064880 Treatment Of Cancers Using Pi3 Kinase Isoform Modulators Abandoned View
17849561 Receptor-Based Antagonists Of The Programmed Cell Death 1 (Pd-1) Pathway Abandoned View
16340376 Modulation Of Novel Immune Checkpoint Targets Patented View
17596879 Culture Device Abandoned View
17250988 Let-7 Promotes Anti-Tumor Activity Of Cd8 T Cells And Memory Formation In Vivo Abandoned View
18322450 Chimeric Engulfment Receptor Molecules And Methods Of Use Abandoned View
18363417 Chimeric Antigen Receptors Targeting Abnormal Glycobiology Patented View
17788723 Chimeric Antigen Receptors That Bind To Prostate Specific Membrane Antigen Patented View
16317766 Hdac Inhibitors For Use With Nk Cell Based Therapies Patented View
17061998 Anti-Pd-L1 Antibodies And Antibody-Drug Conjugates Patented View
17720766 Anti-Folr1 Immunoconjugate Dosing Regimens Abandoned View
17280202 Cd146 And Uses Thereof As A Biomarker And As A Therapeutic Target In The Diagnosis And Treatment Of Fibrosis Patented View
18206269 Cd33 Exon 2 Deficient Donor Stem Cells For Use With Cd33 Targeting Agents Abandoned View
18158754 A Cell Lexpressing Two Chimeric Antigen Receptors (Cars) At The Cell Surface Patented View
17829183 Methods Of Treating Cancer Patients With Farnesyltransferase Inhibitors Abandoned View

Appeals Statistics

Purchase Subscription

Subscribe to Premium Examiner Statistics for unlimited access for your law firm.

Disclaimer: We do not provide any guarantees as to the accuracy of the statistics presented above and under
no circumstances will we be liable for any outcome resulting from your reliance on the above statistics.